1728 related articles for article (PubMed ID: 31560247)
41. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.
Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Zauber AG; Knudsen AB; Ladabaum U
Ann Intern Med; 2019 Nov; 171(9):612-622. PubMed ID: 31546257
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
[TBL] [Abstract][Full Text] [Related]
43. Estimating the preferences and willingness-to-pay for colorectal cancer screening: an opportunity to incorporate the perspective of population at risk into policy development in Thailand.
Phisalprapa P; Ngorsuraches S; Wanishayakorn T; Kositamongkol C; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2021; 24(1):226-233. PubMed ID: 33467947
[TBL] [Abstract][Full Text] [Related]
44. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
[TBL] [Abstract][Full Text] [Related]
46. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
[TBL] [Abstract][Full Text] [Related]
47. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
[TBL] [Abstract][Full Text] [Related]
48. The cost-effectiveness of screening for colorectal cancer.
Telford JJ; Levy AR; Sambrook JC; Zou D; Enns RA
CMAJ; 2010 Sep; 182(12):1307-13. PubMed ID: 20624866
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals.
Benamouzig R; Barré S; Saurin JC; Leleu H; Vimont A; Taleb S; De Bels F
Therap Adv Gastroenterol; 2021; 14():17562848211002359. PubMed ID: 33953799
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
51. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.
van Hees F; Habbema JD; Meester RG; Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG
Ann Intern Med; 2014 Jun; 160(11):750-9. PubMed ID: 24887616
[TBL] [Abstract][Full Text] [Related]
52. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
[TBL] [Abstract][Full Text] [Related]
53. Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina.
van der Steen A; Knudsen AB; van Hees F; Walter GP; Berger FG; Daguise VG; Kuntz KM; Zauber AG; van Ballegooijen M; Lansdorp-Vogelaar I
Health Serv Res; 2015 Jun; 50(3):768-89. PubMed ID: 25324198
[TBL] [Abstract][Full Text] [Related]
54. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
55. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
Lee KS; Park EC
Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
[TBL] [Abstract][Full Text] [Related]
56. The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs. colonoscopy.
Wong MC; Ching JY; Chan VC; Sung JJ
Sci Rep; 2015 Sep; 5():13568. PubMed ID: 26338314
[TBL] [Abstract][Full Text] [Related]
57. Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations.
Dinh TA; Alperin P; Walter LC; Smith R
J Gen Intern Med; 2012 Jun; 27(6):730-8. PubMed ID: 22237663
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of a patient navigation intervention to increase colonoscopy screening among low-income adults in New Hampshire.
Rice K; Sharma K; Li C; Butterly L; Gersten J; DeGroff A
Cancer; 2019 Feb; 125(4):601-609. PubMed ID: 30548480
[TBL] [Abstract][Full Text] [Related]
59. Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained service.
Thomas C; Mandrik O; Whyte S; Saunders CL; Griffin SJ; Usher-Smith JA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1344. PubMed ID: 33533190
[TBL] [Abstract][Full Text] [Related]
60. Markov's modeling for screening strategies for colorectal cancer.
Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
